GlassScriptPhysician profile
Edward Medeiros
NPI 1144616715
$46,716.02
in general payments reported to CMS, 2019-2025
31 companies · $6,363 in 2025
The $6,363 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $393 · 2021: $1,910 · 2022: $1,586 · 2023: $11K · 2024: $25K · 2025: $6,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $6,668 · Travel and Lodging: $328 · Education: $267 · Consulting Fee: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,700.00 |
| Food and Beverage | $6,667.59 |
| Travel and Lodging | $328.30 |
| Education | $267.22 |
| Consulting Fee | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39,353.98 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $782.89 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $643.26 | 2021-2025 | |
| Vifor Pharma, INC. | $615.88 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $562.70 | 2020-2025 | Tavneos, Aranesp, Parsabiv |
| Glaxosmithkline, LLC. | $481.15 | 2021-2025 | Benlysta |
| Calliditas Therapeutics US INC. | $431.18 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $402.78 | 2020-2024 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.62 | 2020-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $377.20 | 2019-2025 | Ultomiris |
| Fresenius USA Marketing, INC. | $350.83 | 2020-2025 | Velphoro, Velphoro, Korsuva |
| Aurinia Pharma U.S., INC. | $311.44 | 2021-2025 | Lupkynis |
| Akebia Therapeutics INC | $223.67 | 2021-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $214.89 | 2022-2025 | Filspari |
| Horizon Therapeutics Plc | $207.54 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $165.10 | 2021 | |
| Azurity Pharmaceuticals, INC. | $153.78 | 2023-2024 | Edarbi, Edarbi |
| Arbor Pharmaceuticals, INC. | $133.41 | 2020-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $131.50 | 2022-2025 | Voyxact |
| Novo Nordisk INC | $131.06 | 2025 | Ozempic, Wegovy |
| Vantive US Healthcare LLC | $116.44 | 2025 | Renal - Pd |
| Ardelyx, INC. | $110.19 | 2023-2024 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $96.59 | 2022-2025 | Terlivaz |
| Nxstage Medical, INC. | $79.54 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $66.13 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $55.26 | 2022-2024 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $35.28 | 2024 | |
| Novartis Pharmaceuticals Corporation | $28.84 | 2025 | |
| Cmp Pharma, INC. | $27.08 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.09 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Medeiros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.